CN113395996B - 精氨酸酶抑制剂及其使用方法 - Google Patents

精氨酸酶抑制剂及其使用方法 Download PDF

Info

Publication number
CN113395996B
CN113395996B CN202080012567.4A CN202080012567A CN113395996B CN 113395996 B CN113395996 B CN 113395996B CN 202080012567 A CN202080012567 A CN 202080012567A CN 113395996 B CN113395996 B CN 113395996B
Authority
CN
China
Prior art keywords
cancer
butyl
tert
pharmaceutically acceptable
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080012567.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN113395996A (zh
Inventor
S·N·姆利纳斯基
T·格雷贝
S·卡瓦特卡
M·R·V·芬莱
I·辛普森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN113395996A publication Critical patent/CN113395996A/zh
Application granted granted Critical
Publication of CN113395996B publication Critical patent/CN113395996B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202080012567.4A 2019-02-08 2020-02-07 精氨酸酶抑制剂及其使用方法 Active CN113395996B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962802765P 2019-02-08 2019-02-08
US62/802765 2019-02-08
PCT/IB2020/050982 WO2020161675A1 (en) 2019-02-08 2020-02-07 Arginase inhibitors and methods of use thereof

Publications (2)

Publication Number Publication Date
CN113395996A CN113395996A (zh) 2021-09-14
CN113395996B true CN113395996B (zh) 2024-05-28

Family

ID=69770954

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080012567.4A Active CN113395996B (zh) 2019-02-08 2020-02-07 精氨酸酶抑制剂及其使用方法

Country Status (32)

Country Link
US (2) US12435097B2 (cg-RX-API-DMAC7.html)
EP (1) EP3921033B1 (cg-RX-API-DMAC7.html)
JP (1) JP7526734B2 (cg-RX-API-DMAC7.html)
KR (1) KR102759971B1 (cg-RX-API-DMAC7.html)
CN (1) CN113395996B (cg-RX-API-DMAC7.html)
AU (1) AU2020218651B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021015581A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021002056A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021011039A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210463A (cg-RX-API-DMAC7.html)
DK (1) DK3921033T3 (cg-RX-API-DMAC7.html)
DO (2) DOP2021000166A (cg-RX-API-DMAC7.html)
EA (1) EA202192114A1 (cg-RX-API-DMAC7.html)
ES (1) ES2960034T3 (cg-RX-API-DMAC7.html)
FI (1) FI3921033T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20231092T1 (cg-RX-API-DMAC7.html)
HU (1) HUE062968T2 (cg-RX-API-DMAC7.html)
IL (1) IL285108B2 (cg-RX-API-DMAC7.html)
LT (1) LT3921033T (cg-RX-API-DMAC7.html)
MA (1) MA56324B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021009499A (cg-RX-API-DMAC7.html)
MY (1) MY206577A (cg-RX-API-DMAC7.html)
PE (1) PE20220280A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021551902A1 (cg-RX-API-DMAC7.html)
PL (1) PL3921033T3 (cg-RX-API-DMAC7.html)
PT (1) PT3921033T (cg-RX-API-DMAC7.html)
RS (1) RS64781B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202108503PA (cg-RX-API-DMAC7.html)
SI (1) SI3921033T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300337T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020161675A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202105833B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202007739XA (en) * 2018-02-17 2020-09-29 Astrazeneca Ab Arginase inhibitors and methods of use thereof
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1358187A (zh) * 1999-05-03 2002-07-10 阿斯特拉曾尼卡有限公司 新的化合物
CN104876955A (zh) * 2010-04-22 2015-09-02 马尔斯公司 精氨酸酶抑制剂及其治疗应用
CN106008569A (zh) * 2010-10-26 2016-10-12 马尔斯公司 作为精氨酸酶抑制剂的硼酸盐及其组合物和用途
WO2017175185A1 (en) * 2016-04-08 2017-10-12 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors
CN107406464A (zh) * 2014-12-29 2017-11-28 昂科艾伦迪治疗法股份公司 精氨酸酶抑制剂及其治疗用途
CN108794517A (zh) * 2017-04-27 2018-11-13 南京谷睿生物科技有限公司 一种精氨酸酶抑制剂及其制备方法与用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0300907D0 (sv) * 2003-03-31 2003-03-31 Astrazeneca Ab Novel compounds
WO2010085797A2 (en) 2009-01-26 2010-07-29 The Trustees Of University Of Pennsylvania Arginase inhibitors and methods of use
CA2852685C (en) 2011-10-19 2019-02-26 Mars, Incorporated Inhibitors of arginase and their therapeutic application
RU2671976C2 (ru) 2012-12-17 2018-11-08 Пэрион Сайенсиз, Инк. Соединения 3,5-диамино-6-хлор-n-(n-(4-фенилбутил)карбамимидоил)пиразин-2-карбоксамида
AU2016281620B2 (en) * 2015-06-23 2021-07-22 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
WO2018119440A1 (en) * 2016-12-22 2018-06-28 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
SG11202007739XA (en) * 2018-02-17 2020-09-29 Astrazeneca Ab Arginase inhibitors and methods of use thereof
US12215116B2 (en) * 2018-03-13 2025-02-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
WO2019205979A1 (zh) * 2018-04-27 2019-10-31 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途
MA53427B1 (fr) 2018-08-22 2024-06-28 Astrazeneca Ab Inhibiteurs de l'arginase et leurs méthodes d'utilisation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1358187A (zh) * 1999-05-03 2002-07-10 阿斯特拉曾尼卡有限公司 新的化合物
CN104876955A (zh) * 2010-04-22 2015-09-02 马尔斯公司 精氨酸酶抑制剂及其治疗应用
CN106008569A (zh) * 2010-10-26 2016-10-12 马尔斯公司 作为精氨酸酶抑制剂的硼酸盐及其组合物和用途
CN107406464A (zh) * 2014-12-29 2017-11-28 昂科艾伦迪治疗法股份公司 精氨酸酶抑制剂及其治疗用途
WO2017175185A1 (en) * 2016-04-08 2017-10-12 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors
CN108794517A (zh) * 2017-04-27 2018-11-13 南京谷睿生物科技有限公司 一种精氨酸酶抑制剂及其制备方法与用途

Also Published As

Publication number Publication date
DK3921033T3 (da) 2023-10-16
AU2020218651B2 (en) 2023-01-12
MY206577A (en) 2024-12-24
JP2022521474A (ja) 2022-04-08
KR102759971B1 (ko) 2025-01-23
DOP2021000166A (es) 2021-09-30
HRP20231092T1 (hr) 2023-12-22
IL285108B1 (en) 2024-06-01
IL285108A (en) 2021-09-30
MX2021009499A (es) 2021-09-08
KR20210126044A (ko) 2021-10-19
PL3921033T3 (pl) 2024-01-15
BR112021015581A2 (pt) 2021-10-05
HUE062968T2 (hu) 2023-12-28
CL2021002056A1 (es) 2022-03-04
ZA202105833B (en) 2025-03-26
ES2960034T3 (es) 2024-02-29
PE20220280A1 (es) 2022-02-25
CR20210463A (es) 2021-10-15
IL285108B2 (en) 2024-10-01
WO2020161675A1 (en) 2020-08-13
CN113395996A (zh) 2021-09-14
US20220106335A1 (en) 2022-04-07
RS64781B1 (sr) 2023-11-30
EA202192114A1 (ru) 2021-12-01
SG11202108503PA (en) 2021-09-29
EP3921033B1 (en) 2023-07-26
JP7526734B2 (ja) 2024-08-01
US12435097B2 (en) 2025-10-07
CA3127755A1 (en) 2020-08-13
PH12021551902A1 (en) 2022-08-01
SMT202300337T1 (it) 2023-11-13
FI3921033T3 (fi) 2023-09-15
EP3921033A1 (en) 2021-12-15
SI3921033T1 (sl) 2023-11-30
LT3921033T (lt) 2023-09-25
CO2021011039A2 (es) 2021-09-09
AU2020218651A1 (en) 2021-09-30
US20250282800A1 (en) 2025-09-11
MA56324B1 (fr) 2023-10-31
DOP2024000181A (es) 2024-10-15
PT3921033T (pt) 2023-10-11

Similar Documents

Publication Publication Date Title
JP7699171B2 (ja) アルギナーゼインヒビタ及びその使用方法
US20250282800A1 (en) Arginase inhibitors and methods of use thereof
HK40062935A (en) Arginase inhibitors and methods of use thereof
HK40065571B (en) Arginase inhibitors and methods of use thereof
HK40065571A (en) Arginase inhibitors and methods of use thereof
EA044999B1 (ru) Ингибиторы аргиназы и способы их применения
JP7579324B2 (ja) アルギナーゼ阻害剤及びその使用方法
HK40037636B (en) Arginase inhibitors and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40062935

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant